Mirum Pharmaceuticals (NASDAQ:MIRM) Now Covered by Stifel Nicolaus

Analysts at Stifel Nicolaus began coverage on shares of Mirum Pharmaceuticals (NASDAQ:MIRM) in a report issued on Wednesday, MarketBeat reports. The brokerage set a “buy” rating and a $48.00 price target on the stock. Stifel Nicolaus’ price objective points to a potential upside of 103.65% from the company’s current price.

A number of other equities research analysts have also commented on the company. JMP Securities raised their price target on Mirum Pharmaceuticals from $69.00 to $72.00 and gave the stock an “outperform” rating in a research report on Thursday, March 14th. SVB Leerink lowered their price objective on shares of Mirum Pharmaceuticals from $44.00 to $43.00 and set an “outperform” rating for the company in a research report on Monday, March 18th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $35.00 price objective on shares of Mirum Pharmaceuticals in a research report on Thursday, February 29th. HC Wainwright reiterated a “buy” rating and set a $58.00 target price on shares of Mirum Pharmaceuticals in a report on Tuesday, April 2nd. Finally, Raymond James cut their price target on Mirum Pharmaceuticals from $78.00 to $64.00 and set a “strong-buy” rating on the stock in a report on Tuesday, December 19th. Eight equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $51.70.

Mirum Pharmaceuticals Trading Down 1.2 %

Shares of MIRM opened at $23.57 on Wednesday. The stock’s fifty day simple moving average is $26.97 and its 200-day simple moving average is $28.52. The firm has a market capitalization of $1.11 billion, a PE ratio of -5.94 and a beta of 1.14. Mirum Pharmaceuticals has a 12-month low of $23.29 and a 12-month high of $35.56. The company has a quick ratio of 4.19, a current ratio of 4.45 and a debt-to-equity ratio of 1.23.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings data on Wednesday, February 28th. The company reported ($0.66) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.32). The company had revenue of $69.55 million during the quarter, compared to the consensus estimate of $66.73 million. Mirum Pharmaceuticals had a negative net margin of 86.33% and a negative return on equity of 66.24%. As a group, research analysts predict that Mirum Pharmaceuticals will post -1.12 earnings per share for the current year.

Insider Activity at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, COO Peter Radovich sold 4,303 shares of the firm’s stock in a transaction dated Monday, March 25th. The stock was sold at an average price of $25.80, for a total value of $111,017.40. Following the sale, the chief operating officer now owns 29,013 shares of the company’s stock, valued at approximately $748,535.40. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other Mirum Pharmaceuticals news, COO Peter Radovich sold 4,303 shares of the business’s stock in a transaction on Monday, March 25th. The shares were sold at an average price of $25.80, for a total value of $111,017.40. Following the completion of the sale, the chief operating officer now directly owns 29,013 shares of the company’s stock, valued at $748,535.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Eric Bjerkholt bought 2,000 shares of the business’s stock in a transaction dated Wednesday, March 27th. The stock was purchased at an average price of $24.80 per share, for a total transaction of $49,600.00. Following the acquisition, the chief financial officer now directly owns 14,000 shares of the company’s stock, valued at approximately $347,200. The disclosure for this purchase can be found here. 24.06% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. China Universal Asset Management Co. Ltd. grew its stake in shares of Mirum Pharmaceuticals by 98.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 986 shares of the company’s stock worth $31,000 after acquiring an additional 488 shares during the last quarter. AJOVista LLC bought a new position in Mirum Pharmaceuticals in the 4th quarter worth about $40,000. Wetzel Investment Advisors Inc. purchased a new stake in Mirum Pharmaceuticals during the 4th quarter valued at about $41,000. Tower Research Capital LLC TRC increased its stake in Mirum Pharmaceuticals by 186.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 1,846 shares of the company’s stock valued at $48,000 after purchasing an additional 1,202 shares in the last quarter. Finally, Royal Bank of Canada raised its holdings in Mirum Pharmaceuticals by 40.1% in the second quarter. Royal Bank of Canada now owns 1,851 shares of the company’s stock worth $48,000 after buying an additional 530 shares during the last quarter.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.